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Abstract
Background: Expression of kappa gene is under the control of distinct cis-regulatory elements,
including the kappa intron enhancer (iEκ) and the kappa 3' enhancer (3'Eκ). The active enhancers
and expression of immunoglobulin is generally considered to be restricted to B lymphocytes.
However, accumulating evidence indicated that epithelial cancer cells, including nasopharyngeal
carcinoma (NPC) cell lines, express immunoglobulins. The mechanisms underlying the expression
of Igs in nonlymphoid cells remain unknown. On the basis of our previous finding that expression
of kappa light chain in NPC cells can be upregulated by EBV-encoded latent membrane protein
1(LMP1) through the activation of NF-κB and AP-1 signaling pathways, we thus use NPC cells as
model to further explore the molecular mechanisms of nonlymphoid cells expressing Ig kappa.
Results: In this study, luciferase reporter plasmid containing human wild-type iEκ, and its derivative
plasmids containing mutant binding sites for transcription factor NF-κB or AP-1 were constructed.
Luciferase reporter assays demonstrate iEκ is active in Igκ-expressing NPC cells and LMP1
expression can upregulate the activity of iEκ in NPC cells. Mutation of the NF-κB or AP-1 site within
and downstream the iEκ, inhibition of the NF-κB and AP-1 pathways by their respective chemical
inhibitor Bay11-7082 and SP600125 as well as stable or transient expression of dominant-negative
mutant of IκBα (DNMIκBα) or of c-Jun (TAM67) indicate that both sites are functional and LMP1-
enhanced iEκ activity is partly regulated by these two sites. Gel shift assays show that LMP1
promotes NF-κB subunits p52 and p65 as well as AP-1 family members c-Jun and c-Fos binding to
the κNF-κB and the κAP-1 motifs in vitro, respectively. Both chemical inhibitors and dominant
negative mutants targeting for NF-κB and AP-1 pathways can attenuate the LMP1-enhanced
bindings. Co-IP assays using nuclear extracts from HNE2-LMP1 cells reveal that p52 and p65, c-Jun
and c-Fos proteins interact with each other at endogenous levels. ChIP assays further demonstrate
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p52 and p65 binding to the κB motif as well as c-Jun and c-Fos binding to the AP-1 motif of Ig kappa
gene in vivo.
Conclusion: These results suggest that human iEκ is active in Igκ-expressing NPC cells and LMP1-
stimulated NF-κB and AP-1 activation results in an augmenting activation of the iEκ. LMP1
promotes the interactions of heterodimeric NF-κB (p52/p65) and heterodimeric AP-1 (c-Jun/c-
Fos) transcription factors with the human iEκ enhancer region are important for the upregulation
of kappa light chain in LMP1-positive nasopharyngeal carcinoma cells.
Background
While considerable evidence has shown that immu-
noglobulins (Igs) "unexpectly" expressed in malignant
tumors of epithelial origin [1-10], much less is known
about the molecular mechanisms of nonlymphoid cells
expressing Igs. In our previous work, we have also demon-
strated that nonlymphoid NPC cells express immu-
noglobulin kappa light chain. In addition, we have found
that EBV-encoded latent membrane protein 1 (LMP1) can
upregulate the expression of kappa light chain in NPC
cells and both NF-κB and AP-1 signaling pathways are
involved in LMP1-augmented kappa light chain expres-
sion [1]. These results promote us using of NPC cell lines
as model to further explore the mechanisms underlying
the expression of Ig kappa in nonlymphoid cells.
Expression of kappa light chain gene is under the control
of distinct cis-regulatory elements, including the kappa
intron enhancer (iEκ) and the kappa 3' enhancer (3'Eκ)
[11,12], which are located within the Jκ-Cκ region and
downstream of Cκ region, respectively. Both enhancers are
inactive at the pro-B and pre-B cell stages and active at the
Igκ-expressing mature B cell and plasma cell stages. The
activity of these enhancers in other non-kappa-producing
cell lineages, such as T-lymphoid cells, epithelial cells and
NIH3T3 fibroblasts, is generally silent [11,13]. Base on
these, it is generally believed that the activation of iEκ and
3'Eκ is required for immunoglobulin kappa gene expres-
sion and is B cell lineage-restricted events [14,15]. An
interesting feature of kappa gene transcription is its induc-
ibility. Certain agents, such as cycloheximide (CYC),
phorbol esters and bacterial product lipopolysaccharide
(LPS) can induce the activation of kappa enhancers and
result in kappa gene expression at the pre-B cell stage [16].
Nucleation of transcription factors PU.1, PIP, c-Fos and c-
Jun on the kappa 3' enhancer core can cause a very dra-
matic induction in 3'Eκ activity in NIH3T3 fibroblasts, a
cell in which the enhancer is normally silent [13]. These
findings reinforce the possibility of nonlymphoid cells
expressing Ig kappa by certain unidentified mechanisms
and suggest that other extracellular factors, such as gene
products encoded by viruses, are also likely to induce
kappa enhancers' activation, finally result in kappa gene
transcription and expression.
One viral protein, latent membrane protein 1, is consid-
ered as a major oncogenic protein encoded by EBV for its
transform and tumorigenic activities and is found to be
able to transform cell lines and alter the phenotype of cells
due to its oncogenic potential [17]. Biologically, LMP1 is
an integral membrane protein with six transmembrane
segments that facilitate self-aggregation in the plasma
membrane and transduces ligand-independent signals,
including NF-κB, c-Jun-NH2-terminal kinase (JNK), p38/
MAPK, Ras/MEK/ERK/MAPK, PI3K/Akt and JAK/STAT
[18-23]. The nuclear factor κB (NF-κB) and c-Jun N-termi-
nal kinase (JNK) signaling pathways are the most impor-
tant, since their activation results in the overexpression of
most LMP1 target genes [24]. LMP1 can mimic CD40 sig-
naling to induce B cell activation and differentiation in
vivo. They share some molecules such as TRAF1, 2, 3, and
5 as signal transducers as well as some pathways such as
NF-κB, JNK, p38/MAPK, PI3K/Akt and JAK/STAT path-
ways [25]. In normal B cells, an important mechanism of
Ig production is CD40 ligation-triggered cellular signaling
pathways [26]. In addition, it has been found that CD40
signaling can increase IgH 3' enhancer activity [27]. These
studies, in combination with our previous finding that
kappa light chain is significantly higher in LMP1-positive
than in LMP1-negative NPC cells [1], we thus speculate
that upregulation the expression of kappa light chain by
LMP1 may be the result of LMP1-induced kappa
enhancer's activation in NPC cells.
The function of enhancers is mediated by DNA binding
proteins that recruit to the enhancer [12]. Multiple pro-
tein binding sites have been identified and characterized
in each of the kappa enhancers. A κB binding site within
the iEκ and the activity of iEκ is mainly dependent on the
nuclear factor NF-κB binding to κB element [28,29]. Dele-
tion or mutation of the κB site abolishes the activity of iEκ,
suggesting it might as a crucial enhancer element [16,30].
In addition, the human kappa gene Jκ-Cκ region also con-
tains a perfect consensus AP-1 site, which located ~320
bases downstream of the κB site. The κAP-l site in the con-
text of the iEκ can positively regulate the iEκ activity and
kappa expression in B cells, suggests that it plays a role in
kappa gene regulation [31]. However, in Igκ-expressing
nonlymphoid cells, whether these two binding sites play
roles in functional activation of iEκ is still unknown.Molecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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Since kappa enhancers' activation is required for Ig kappa
gene expression and their activations are generally consid-
ered as B cell lineage-restricted events, and since NF-κB
and AP-1 binding sites exist within and downstream the
iEκ enhancer, and on the basis of our previous findings
that both NF-κB and AP-1 pathways are involved in
LMP1-augmented Ig kappa expression in human NPC
cells, we therefore focus on the iEκ enhancer and attempt
to study further whether it is active in Igκ-expressing NPC
cells and whether LMP1-upregulated kappa expression is
correlated with the activation of iEκ via NF-κB and AP-1
pathways. In this study, luciferase reporter analysis dem-
onstrate that the iEκ  whose activation is required for
immunoglobulin kappa gene expression indeed activates
in Igκ-expressing NPC cells and stable or transient LMP1
expression can upregulate the activity of iEκ in NPC cells.
Moreover, mutation analysis of κB or AP-1 binding site
within or downstream the iEκ, inhibition of LMP1-medi-
ated NF-κB and AP-1 signaling pathways by using specific
chemical inhibitors and dominant inhibitory molecules
indicate that both sites are functional and LMP1-
enhanced iEκ activity is regulated, to some extent, through
these two sites. Gel shift assays show that LMP1 promotes
NF-κB subunits p52 and p65 as well as AP-1 family mem-
bers c-Jun and c-Fos binding to the κNF-κB and the κAP-
1 motifs in vitro, respectively. Both chemical inhibitors
and dominant negative mutants targeting for NF-κB and
AP-1 pathways can attenuate theLMP1-enhanced bind-
ings. Co-IP assays using nuclear extracts from HNE2-
LMP1 cells reveal that p52 and p65, c-Jun and c-Fos pro-
teins interact with each other at endogenous levels. ChIP
assays further demonstrate p52 and p65 binding to the κB
motif as well as c-Jun and c-Fos binding to the AP-1 motif
of Ig kappa gene in vivo. Based on the findings reported
here, we conclude that the iEκ enhancer is active in NPC
cells and is further activated by LMP1 via NF-κB and AP-1
pathways, which contributes to the upregulation of Ig
kappa by LMP1 in NPC cells.
Results
Activation of the human immunoglobulin kappa intron 
enhancer in Ig -expressing nasopharyngeal carcinoma cells
Immunoglobulin kappa gene expression is under the con-
trol of distinct cis-regulatory elements, including the iEκ
and the 3'Eκ [11,12]. The activity of these enhancers is
believed to contribute to Ig kappa expression in B cell
lines [14]. In order to investigate if the iEκ enhancer could
be functionally activated in NPC cells, we linked the iEκ to
the Iα-promoter driving the transcription of the luciferase
reporter gene and analyzed this reporter construct in tran-
sient transfection of NPC cell lines. A schematic diagram
of the Ig kappa intron enhancer regions that were cloned
was shown in Fig. 1A, and the wild-type reporter construct
was illustrated in Fig. 1B. As shown in Fig. 1B, a 575 bp
genomic fragment containing the intact iEκ was subcloned
into the enhancerless pGL3-α plasmid. This construct,
which containing wild-type κB site within the iEκ and
wild-type AP-1 site downstream the 3' flank of the iEκ
(designated as pα-iEκwt), was introduced into HNE2 and
HNE2-LMP1 cells to test the activity of iEκ. The human Iα
promoter we used was identical to that used previously
[32] and we found it to be minimally affected by LMP1 in
our experiments (Fig. 1, C and 1D). Transfection of pα-
iEκwt generated higher luciferase activities than that of the
pGL3-α construct whether in LMP1-negative (P < 0.01) or
in LMP1-positive (P < 0.01) NPC cells (Fig. 1, C and 1D).
Notably, the luciferase activity of pGL3-α in both HNE2
and HNE2-LMP1 cells was essentially equivalent, which
suggested that the functional specificities of the iEκ
enhancer in NPC cells were due to the enhancer itself
rather than the promoter sequences. These results indicate
that the iEκ is active in NPC cells which express immu-
noglobulin kappa light chain.
Increases the activity of human immunoglobulin kappa 
intron enhancer by LMP1 in nasopharyngeal carcinoma 
cells
We found previously that EBV-LMP1 upregulates Ig kappa
light chain expression in nasophayngeal epithelial cells
[1]. In order to investigate whether the upregulation effect
was due to LMP1-enhannced iEκ  activity, luciferase
reporter assays were performed to compare the iEκ activity
in LMP1-positive and -negative NPC cells. The results
indicated that the activity of iEκ in HNE2-LMP1 cells was
significantly higher than that in HNE2 cells (Fig. 1C, 53.5
vs. 17.7, P < 0.01), which was in line with the kappa chain
expression patterns of these two cell lines [1]. Similar
results were obtained with transient transfection of LMP1
into HNE2 cells (Fig. 1D). These results indicate that
LMP1 can enhance the iEκ activity. We thus infer that
LMP1 can increase the activity of iEκ and the upregulation
of kappa light chain by LMP1 is likely due to increase the
activity of iEκ by LMP1.
Involvement of NF- B and AP-1 signaling pathways in 
LMP1-increased human kappa intron enhancer activity
Based on the previous finding that both NF-κB and AP-1
signaling pathways are involved in LMP1-augmented
kappa light chain expression [1], to determine whether
either the NF-κB or the AP-1 sequence was required for
LMP1-enhanced iEκ activity, site-directed mutagenesis by
overlap extension PCR was used to introduce mutations
into each of these sequences. From the pα-iEκwt construct,
we created constructs termed pα-iEκ-mtκB and pα-iEκ-
mtAP-1, respectively (Fig. 2A). These constructs were
introduced individually into human nasopharyngeal car-
cinoma cell lines to test the activity of iEκ. As shown in Fig.
2B, mutation of the NF-κB or the AP-1 motif significantly
decreased LMP1-increased iEκ activity (p < 0.01 and p <
0.05, respectively). In addition, the magnitude of theMolecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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reduction for pα-iEκ-mtAP-1 was less than that for pα-iEκ-
mtκB, implying that of two signaling pathways, NF-κB
pathway might play a leading role in LMP1-augmented
iEκ activity in NPC cells. The activity of iEκ in HNE2 cells
was moderately decreased by these genetic manipula-
tions. Combination this with the results that mutation of
either the NF-κB or the AP-1 motif could not completely
abolish the iEκ activity in NPC cells as well as previous
reports that several additional functional motifs are
located within the iEκ [33,34], suggested that the variety of
Activation of the iEκ enhancer and enhancement of the iEκ activity by LMP1 in human nasopharyngeal carcinoma cells Figure 1
Activation of the iEκ enhancer and enhancement of the iEκ activity by LMP1 in human nasopharyngeal carci-
noma cells. (A) Schematic diagram of human iEκ-containing DNA fragment used in these experiments. Position of the iEκ, the 
NF-κB and the AP-1 binding sites were shown. For simplicity, other protein-binding sites in the iEκ were not shown. (B) Inser-
tion sites for the definite DNA fragment into the pGL3-α plasmid which contains the human immunoglobulin Iα promoter and 
the firefly luciferase reporter gene. (C) Comparison of the activities of iEκ in human nasopharyngeal carcinoma cell lines. Tran-
sient transfected the pα-iEκwt construct, pGL3-α or pGL3-Basic vector into HNE2 and HNE2-LMP1 cells and luciferase 
reporter assays were performed as described in Materials and methods. The relative luciferase activity normalized to the value 
of the internal control plasmid pRL-SV40 activity. Results were expressed as fold induction of pGL3-Basic activity, which was 
assigned a value of 1. The data represent the mean ± SD of the three independent experiments performed in triplicate. Statis-
tical significance: # P < 0.01 vs. pGL3-α-transfected HNE2, *P < 0.01 vs. pGL3-α-transfected HNE2-LMP1. (D) Transient 
expression of LMP1 increased the iEκ activity in nasopharyngeal carcinoma cells. HNE2 cells were co-transfected with 400 ng/
well of pα-iEκwt, pGL3-α or pGL3-Basic vector and 80 ng/well of internal control pRL-SV40 together with 200 ng/well of 
pSG5-LMP1 or blank expression plasmid pSG5 (total DNA ~800 ng). Cells were harvested at 36 h after transfection and sub-
jected to luciferase analysis. Statistical significance: # P < 0.01 vs. pSG5-transfected HNE2.
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Mutation of NF-κB or AP-1 binding site attenuated LMP1-increased iEκ activity Figure 2
Mutation of NF-κB or AP-1 binding site attenuated LMP1-increased iEκ activity. (A) Schematic diagram of mutant 
iEκ constructs were shown. The expansion for NF-κB or AP-1 binding site gave its wild-type sequence and the nucleotides 
replaced by mutations were underlined. Arrows indicated nucleotides introduced by mutations. (B) Comparison of the activi-
ties of iEκ in human nasopharyngeal carcinoma cell lines. Transient transfected the constructs carrying wild-type NF-κB and AP-
1 sequences (pα-iEκwt), mutant NF-κB sequence (pα-iEκ-mtκB), mutant AP-1 sequence (pα-iEκ-mtAP-1), pGL3-α or pGL3-
Basic into HNE2 and HNE2-LMP1 cells and luciferase reporter assays were performed as described in Materials and methods. 
The relative luciferase activity normalized to the value of the internal control plasmid pRL-SV40 activity. Results were 
expressed as fold induction of pGL3-Basic activity, which was assigned a value of 1. The data represent the mean ± SD of the 
three independent experiments performed in triplicate. Statistical significance: #P < 0.05 vs. pα-iEκwt-transfected HNE2, * P < 
0.01 and ** P < 0.05 vs. pα-iEκwt-transfected HNE2-LMP1.
A
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nuclear factors that can bind to the iEκ may result in com-
plex regulatory pathways. Together, the results indicate
that both NF-κB and AP-1 biding sites contribute to the
basal and the LMP1-induced iEκ activities in NPC cells.
Abrogation of LMP1-augmented human kappa intron 
enhancer activity by inhibitors and dominant negative 
mutants targeting for NF- B and AP-1 pathways
To further confirm both NF-κB and AP-1 sites contributed
to LMP1-augmented iEκ activity, we used various specific
inhibitors and dominant negative mutants for NF-κB and
AP-1 signaling pathways to block the LMP1-mediated iEκ
activation. As shown in Fig. 3A, LMP1-induced iEκ activity
was significantly inhibited by 20 μM Bay11-7082 (p <
0.01) or 20 μM SP600125 (p < 0.05) but not by the
DMSO vehicle control. These two compounds also
decreased the iEκ activity in HNE2 cells to a certain extent
but did not have statistical difference (P > 0.05), which
was consistent with the previous immunoblot results that
both compounds have no obvious inhibitory effects on
kappa expression in HNE2 cells [1]. It was reported
Bay11-7082 reduces only the constitutive but not the
inducible activity of NF-κB [35]. We speculated SP600125
might reduce only the constitutive but not the inducible
activity of JNK as did Bay11-7082, which might explain
why both of them were not capable of decreasing the iEκ
activity and kappa expression in HNE2 cells. Moreover, 20
μM Bay11-7082 showed more inhibitory effect on the
activity of iEκ than 20 μM SP600125. We have found that
the amount of kappa light chain in HNE2-LMP1-
DNMIκBα and HNE2-LMP1-TAM67 cell lines is signifi-
cantly lower than that in their parental cell line HNE2-
LMP1 [1]. We therefore investigated whether the down-
regulation of kappa chain was correlated with the iEκ
activity in the same cell lines. The results showed that the
augmenting effect of iEκ activity by LMP1 was obviously
attenuated when DNMIκBα and TAM67 were stably tran-
fected into HNE2-LMP1 cells (Fig. 3B). Transient co-trans-
fection of DNMIκBα or TAM67 with LMP1 into HNE2
cells significantly declined the LMP1-upregulated iEκ
activity (Fig. 3C). Together, these results again indicate
that both NF-κB and AP-1 pathways play roles in the
LMP1-upregulated iEκ activity in NPC cells.
LMP1 promotes p52 and p65 binding to the  NF- B motif 
as well as c-Jun and c-Fos binding to the  AP-1 motif in vitro
We demonstrated that the activity of iEκ was upregulated
in HNE2-LMP1 cells and the activity of iEκ in the experi-
mental NPC cell lines was consistent with their kappa
chain expression patterns. To further investigate whether
there was any correlation between our reporter expression
and transcription factor binding activities of the DNA
fragments covering the NF-κB and AP-1 motifs from the
iEκ-containing Jκ-Cκ region of human kappa gene, we per-
formed electrophoresis mobility shift assays to examine
the protein complexes formed with κNF-κB and κAP-1
motifs at NPC cell lines. Biotin-labeled double-stranded
κNF-κB and κAP-1 oligonucleotide probes as well as
equal amounts of nuclear extracts from HNE2, HNE2-
LMP1, HNE2-LMP1-DNMIκBα, HNE2-LMP1-TAM67,
Bay11-7082-treated HNE2-LMP1 and SP600125-treated
HNE2-LMP1 cells were used. As Fig. 4A shown, LMP1
caused a much stronger NF-κB DNA binding activity in
HNE2-LMP1 cells than that in HNE2 cells (lane 2 vs. lane
3). The nuclear lysates isolated from HNE2-LMP1-
DNMIκBα cells induced a weaker electromobility shift
band than that from their parental cells HNE2-LMP1
(lane 3 vs. lane 4). We also found that the induction of
NF-κB DNA binding activity by LMP1 was clearly inhib-
ited by 20 μM Bay11-7082 (lane 3 vs. lane 5). To demon-
strate the specificity of these interactions, competitive
binding assays were performed. Excess unlabeled double-
stranded  κNF-κB oligonucleotide was included in the
binding assay mixtures. A 200-fold excess of unlabeled
oligonucleotide could completely compete for the protein
binding seen with the HNE2-LMP1 cell extracts (lane 6).
However, the same excess of the unlabeled mutant κNF-
κB oligonucleotide (lane 7) or oligonucleotide containing
the κAP-1 binding motif (lane 8) did not compete for the
complex. In addition, the nuclear lysates isolated from
these cell lines did not induce an electromobility shift
when biotin-labeled κNF-κB mutant-type oligonucleotide
was introduced (Fig. 4B). These implied that the complex
formed with extracts was specific to the sequence of the
κNF-κB oligonucleotide. To characterize the composition
of the DNA-bound NF-κB complex, we performed super-
EMSA with antibodies specific for NF-κB family members
p50, p52, p65, c-Rel and RelB to analyze the nuclear
extracts of HNE2-LMP1 cells. As shown in Fig. 4C, the
addition of p50, c-Rel and RelB antibody did not influ-
ence the mobility or intensity of the NF-κB binding com-
plex (lanes 4, 7 and 8), whereas the addition of antibodies
for p52 and p65 resulted in a significant diminishment or
supershift of the specific complex (lanes 5 and 6). A con-
trol IgG antibody failed to attenuate the shift or elicit a
supershift (lane 9). The results indicate the presence of
p52 and p65 proteins in the complex with the kappa NF-
κB binding site. We further tested the effect of LMP1 on
p65 and p52 expression. Though no obvious difference of
p65 level in HNE2 and HNE2-LMP1 cells (Fig. 4D), by
separating cytoplasmic and nuclear fractions, we found
LMP1 led to p65 nuclear translocation (Fig. 4E). We also
found LMP1 induced the processing of p100 to p52 (Fig.
4F) and the nuclear translocation of p52 (Fig. 4G). Effi-
cient separation of the cytoplasmic and nuclear fractions
was demonstrated by western blotting for cytoplasmic (α-
tubulin) and nuclear (nucleolin) markers [36,37]. We
next examined whether the interaction of p65 and p52
could be observed at endogenous levels. For this purpose,
co-immunoprecipitation (co-IP) experiments were per-Molecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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Inhibitors and dominant negative mutants targeting for NF-κB and AP-1 pathways attenuated LMP1-augmented human iEκ  activities Figure 3
Inhibitors and dominant negative mutants targeting for NF-κB and AP-1 pathways attenuated LMP1-aug-
mented human iEκ activities. (A) Bay11-7082 and SP600125 inhibited the activities of iEκ induced by stable expression 
LMP1. HNE2 and HNE2-LMP1 cells were transfected with pα-iEκwt, pGL3-α or pGL3-Basic vector, and pRL-SV40 as an inter-
nal control for transfection efficiency. 24hr after transfection, cells were treated with Bay11-7082 (20 μM), SP600125 (20 μM) 
or 0.1% DMSO for 12hr. Cells were harvested at 36 h after transfection and subjected to the luciferase assay. Statistical signif-
icance: * P < 0.01 and ** P < 0.05 vs. HNE2-LMP1 vehicle control. (B) Stable expression DNMIκBα and TAM67 inhibited the 
activities of iEκ increased by LMP1. Indicated NPC cell lines were transfected with pα-iEκwt, pGL3-α or pGL3-Basic vector, and 
pRL-SV40 as an internal control for transfection efficiency. Cells were harvested at 36 h after transfection and subjected to the 
luciferase assay. Statistical significance: * P < 0.01 and ** P < 0.05 vs. HNE2-LMP1 control. (C) Both DNMIκBα and TAM67 
inhibited the activities of iEκ induced by transient expression LMP1. HNE2 cells were co-transfected with 400 ng/well of pα-
iEκwt, pGL3-α or pGL3-Basic vector and 80 ng/well of internal control pRL-SV40 together with 200 ng/well of pSG5-LMP1, 
pDNMIκBα or pTAM67 expression plasmid. The total amount of DNA (~800 ng) was kept constant by addition of blank 
expression plasmid pSG5 necessary to normalize the amount of DNA transfected. Cells were harvested at 36 h after transfec-
tion and subjected to the luciferase assay. Statistical significance: # P < 0.01 vs. pSG5-transfected HNE2, * P < 0.01 and ** P < 
0.05 vs. pSG5-LMP1-transfected HNE2.
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formed with non-denatured nuclear extracts from human
nasopharyngeal carcinoma cell line HNE2-LMP1. As
shown in Fig. 5, the p65 antibody could specifically copre-
cipitate endogenous p52 (Fig. 5, upper panel, compare lane
2 using p65 with lane 3 using control IgG antibody).
Endogenous p65 could also be detected in a reverse co-IP
experiment using p52 antibody in the IP step (Fig. 5, lower
panel, lane 5). IgG was used as a negative control in the IP
reaction. The protein input was shown as indicated. These
results reveal a heterodimerization between p65 and p52,
which is likely relevant to kappa light chain expression
upregulated by LMP1 in NPC cells.
Similarly, LMP1 increased the formation of AP-1 DNA
binding complex (Fig. 6A, lane 2 vs. lane 3). The nuclear
lysates isolated from HNE2-LMP1-TAM67 cells induced a
weaker electromobility shift band than that from their
parent cells HNE2-LMP1 (Fig. 6A, lane 3 vs. lane 4). The
induction of AP-1 DNA binding activity by LMP1 was
clearly inhibited by 20 μM SP600125 (Fig. 6A, lane 3 vs.
lane 5). Protein binding to the κAP-1 probe was com-
pletely abrogated by a 200-fold excess of unlabeled wild-
type κAP-1 probe (Fig. 6A, lane 6), but not by the same
excess of unlabeled oligonucleotide probe containing
mutation in the κAP-1 sequence (Fig. 6A, lane 7) and
unlabeled κNF-κB probe (Fig. 6A, lane 8). On the other
hand, the nuclear lysates isolated from these cells did not
induce an electromobility shift when biotin-labeled κAP-
1 mutant-type oligonucleotide was introduced (Fig. 6B).
These implied that the complex formed with extracts was
specific to the sequence of the κAP-1 oligonucleotide. To
gain more insight into the composition of the protein
complex bound to the human κAP-1 motif, we performed
supershift analysis using nuclear extracts from HNE2-
LMP1 cells. The addition of c-Jun antibody into the
nuclear extracts of HNE2-LMP1 cells supershifted the
complex (Fig. 6C, lane 3). Exposure of nuclear extracts
from HNE2-LMP1 cells to c-Fos antibody and subsequent
precipitation of the formed immune complex reduced the
intensity of protein-DNA interaction by approximately
50% (Fig. 6C, lane 4). The super-EMSA results suggest that
c-Jun and c-Fos are components of the complex bound to
the human kappa AP-1 motif. Moreover, we found LMP1
could significantly upregulate JNK phosphorylation ([1]
and Fig. 6D) and simultaneously upregulate the phospho-
rylation level of c-Jun at Ser63 and Ser73 in the nucleus
(Fig. 6D). However, expression of c-Jun and c-Fos were
essentially equal in HNE2 and HNE2-LMP1 cells ([1] and
Fig. 6E). These results implied that LMP1-increased JNK
activation led to the increased phosphorylation of c-Jun at
Ser63 and Ser73, which might promote the JNK substrate
c-Jun heterodimerize with c-Fos to form the AP-1 com-
plex. To examine if c-Jun endogenously interacts with c-
Fos, we performed co-IP experiments. As shown in Fig. 7,
co-IP performed with anti-c-Jun antibody showed the co-
precipitation with c-Fos from non-denatured nuclear
extracts of HNE2-LMP1 cells (Fig. 7, upper panel, lane 2).
Likewise, co-IP using anti-c-Fos antibody displayed c-Jun
protein (Fig. 7, lower panel, lane 5). IgG was applied as a
negative control in the IP reaction. The protein input was
shown as indicated. These data show that the endogenous
c-Jun and c-Fos associate in vivo.
Taken together, the results indicate that p52/p65 and c-
Jun/c-Fos heterodimers can bind to the κB and the AP-1
site of human Ig kappa gene in vitro, respectively, which
may be the key events in upregulating the activity of iEκ by
LMP1 in NPC cells.
LMP1 promotes p52/p65 binding to the  NF- B motif as 
well as c-Jun/c-Fos binding to the  AP-1 motif in vivo
To better understand p52/p65 and c-Jun/c-Fos heterodim-
ers in the regulation of the human iEκ in vivo, we analyzed
the fragments that span the NF-κB and the AP-1 binding
regions within and downstream the iEκ using a chromatin
immunoprecipitation assay (ChIP), respectively. The
HNE2-LMP1 cells were treated with 1% formaldehyde to
cross-link proteins to chromatin and the cross-linked
chromatin was then sheared to fragments of ~500 bp in
length via sonication (Fig. 8A). The sheared cross-linked
chromatin was subsequently subjected to immunoprecip-
itation reactions using antibodies specific for the NF-κB
family members p50, p52, p65, c-Rel and RelB as well as
AP-1 family members c-Jun and c-Fos. An anti-IgG anti-
body was used as a nonspecific control. The precipitated
chromatin DNA was then purified and amplified by PCR
using primers specific for the NF-κB or the AP-1 binding
site of Ig kappa gene. As shown in Fig. 8B, the primers for
the human iEκ region containing the NF-κB binding site
produced 159-bp amplicons that could be observed with
the positive control (input chromatin) and when the
chromatin was precipitated with antibodies specific for
p52 and p65. Use of the p50, c-Rel, RelB antibody showed
no positive signal and no amplification was observed with
three negative controls (no chromatin, no antibody, and
IgG). Another set of primers was used to analyze for in vivo
AP-1 binding to the region located downstream the iEκ
encompassing the AP-1 site. As shown in Fig. 8C, the AP-
1 family members c-Jun and c-Fos antibodies could pre-
cipitate sequences that could be PCR-amplified and pro-
duced 188-bp amplicons using this second set of primers.
Therefore, the ChIP results indicate that p52/p65 and c-
Jun/c-Fos transcription factors can exert its regulatory
function through direct binding to the human iEκ
enhancer and the adjacent sequence.Molecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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Discussion
In this article, we showed that the aberrant expression of
Ig kappa light chain in NPC cells. Recent studies have
demonstrated that the expression of Igs is widespread in
epithelial cancers from many organs and includes basi-
cally all kinds of isotypes. Among heavy chains, α chain
for IgA and γ chain for IgG are the mostly identified; but
in light chain, only κ chain but not λ chain is confirmed.
Moreover, several studies indicated that tumor-derived Igs
have certain biological functions. Qiu et al [5] found
induction of cancer cell apoptosis and inhibition of can-
cer growth by blocking tumor-derived IgG, whose light
chain is kappa, using either antisense oligodeoxynucle-
otide or anti-human IgG, thus confirming that IgG
LMP1 increased the binding ability of p52 and p65 transcription factors to κNF-κB motif in vitro Figure 4
LMP1 increased the binding ability of p52 and p65 transcription factors to κNF-κB motif in vitro. (A) Biotin-
labeled wild-type κNF-κB oligonucleotide probe was incubated with nuclear extracts of HNE2, HNE2-LMP1, HNE2-LMP1-
DNMIκBα and Bay11-7082-treated HNE2-LMP1 (20 μM for 12 hr) NPC cells in the presence of a 200-fold excess of unlabeled 
wild-type κNF-κB (lane 6), unlabeled mutant κNF-κB oligonucleotides (designated as mutκB, lane 7) or noncompetitive unla-
beled κAP-1 oligonucleotide (NS, lane 8), and then NF-κB DNA binding activities were examined by EMSA. (B) Biotin-labeled 
mutant κNF-κB oligonucleotide probe was incubated with nuclear extracts of indicated NPC cell lines, and then NF-κB DNA 
binding activities were examined by EMSA. (C) 10 μg of HNE2-LMP1 nuclear extracts were preincubated with biotin-labeled 
κNF-κB oligonucleotide probe in the absence (lane 2) or presence of antibodies directed against different NF-κB subunits p50, 
p52, p65, c-Rel, RelB or control antibody (IgG) (indicated above each lane) and then supershift assays were performed. (D, E) 
Expression and subcelluar distribution of p65 in HNE2 and HNE2-LMP1 cells. Whole cell lysates, cytoplasmic and nuclear frac-
tions were prepared and expression of p65 was estimated by western blotting. Cytosolic protein α-tubulin and nuclear protein 
nucleolin were detected as protein loading controls. (F, G) Expression and subcelluar distribution of p52 in HNE2 and HNE2-
LMP1 cells. Whole cell lysates, cytoplasmic and nuclear fractions were prepared and expression of p52 was estimated by west-
ern blotting. Cytosolic protein α-tubulin and nuclear protein nucleolin were detected as protein loading controls.
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secreted by epithelial cancers has some unidentified
capacity to promote the growth and survival of tumor
cells. We also found that blockade of cancer-derived Ig
alpha suppresses the growth and viability of cancer cells.
Furthermore, we have demonstrated that cancer-derived
Ig alpha promotes the malignant proliferation ability of
cancer cells and increases the access percentage of S phase
from the early mitosis of synchronized cancer cells [38].
These findings support the important role of cancer-
derived Ig as a growth factor of cancer cells. In addition,
By in situ hybridization to analyze kappa constant region
mRNA in different stages of cervical tissue samples, we
found that the expression of kappa constant region mRNA
is markedly increased in uterine cervical epithelia with
dysplasia and carcinoma, as compared with cervicitis,
thus suggesting a closely associated of kappa light chain
expression with cell malignancy and is associated with
increasing tumor grades [10]. Recently, we analyzed the
ADCC immuno-activity of Ig derived from cancer cells
and found that cancer-derived Ig is capable of reacting
with FcR of monocytes and NK cells by its Fc region as
does normal Ig, and to accomplish ADCC with effector
cells (unpublished data). Based on these findings, it may
be hypothesized that cancer-derived Ig could compete
with B cell-derived Ig for the FcR on effector cells, thus
inhibits ADCC and favors tumor immune escape. The
potential biological functions of the tumor-derived Igs
and the finding that nonlymphoid cells expressing Igs
reported by different research groups revealed that this
phenomenon is not a happenchance. However, the mech-
anisms underlying the expression of Igs in nonlymphoid
cells are still unknown. In present study, we focus mainly
on exploring the possible mechanisms by which nonlym-
phoid cells expressed Ig kappa and found that in Igκ-
expressing NPC cells, kappa intron enhancer is activated.
The activity of iEκ can be further activated by LMP1-stim-
ulated NF-κB and AP-1 aberrant activation. It could be
concluded that LMP1 stimulates transcription factors NF-
κB and AP-1 binding to the corresponding site in kappa
gene via NF-κB, JNK/MAPK signal pathways and finally
upregulates kappa light chain induction. Such mecha-
nisms would explain, at least in part, LMP1-positive
human epithelial cancer cells produce immunoglobulins.
The activation of kappa enhancers, whose function is
mediated by proteins binding to the enhancers, is
required for Ig kappa gene expression [12,14,15]. We
found the iEκ is active in both LMP1-negative and LMP1-
positive NPC cells. In LMP1-negative HNE2 cells, the iEκ
activity is relatively low and is in accord with low kappa
expression level. LMP1 can further activate the activity of
iEκ and contributes to the upregulation of Ig kappa in NPC
Co-IP of endogenous p65 and p52 Figure 5
Co-IP of endogenous p65 and p52. Non-denatured nuclear extracts prepared from HNE2-LMP1 cells were immunopre-
cipitated with anti-p65, anti-p52 or control IgG antibody. The immune complexes and the input (10% of the nuclear extracts 
used in the immunoprecipitation step) were analyzed by immunoblotting with antibody specific to p52 (upper panel, lanes 1-3) 
or p65 (lower panel, lanes 4-6). The same membrane was stripped and reprobed to detect p65 (lower panel, lanes 1-3) or p52 
(upper panel, lanes 4-6).Molecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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LMP1 increased the binding ability of c-Jun and c-Fos transcription factors to κAP-1 motif in vitro Figure 6
LMP1 increased the binding ability of c-Jun and c-Fos transcription factors to κAP-1 motif in vitro. (A) Biotin-
labeled wild-type κAP-1 oligonucleotide probe was incubated with nuclear extracts of HNE2, HNE2-LMP1, HNE2-LMP1-
TAM67 and SP600125-treated HNE2-LMP1 (20 μM for 12 hr) NPC cells in the presence of a 200-fold excess of unlabeled 
wild-type κAP-1 (lane 6), unlabeled mutant κAP-1 oligonucleotides (designated as mutAP-1, lane 7) or noncompetitive unla-
beled κNF-κB oligonucleotide (NS, lane 8), and then AP-1 DNA binding activities were examined by EMSA. (B) Biotin-labeled 
mutant κAP-1 oligonucleotide probe was incubated with nuclear extracts of indicated the NPC cell lines, and then AP-1 DNA 
binding activities were examined by EMSA. (C) 10 μg of HNE2-LMP1 nuclear extracts were preincubated with biotin-labeled 
κAP-1 oligonucleotide probe in the absence (lane 2) or presence of antisera directed against c-Jun (lane 3), c-Fos (lane 4) and 
then supershift assays were performed. (D) Phosphorylation levels of JNK and c-Jun in HNE2 and HNE2-LMP1 cells. The 
nuclear extracts were prepared and analyzed with phospho-JNK (Thr183/Tyr185), phospho-c-Jun (Ser63) and phospho-c-Jun 
(Ser73) antibodies, respectively. Nucleolin was acted as a nuclear protein loading control. (E) Expression of c-Jun and c-Fos in 
HNE2 and HNE2-LMP1 cells. Whole cell lysates were prepared and expression of c-Jun and c-Fos was estimated by Western 
blotting. α-tubulin was detected as a protein loading control.
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cells. Our results indicated that mutant of either NF-κB or
AP-1 biding site did not completely abolish the basal and
LMP1-induced iEκ activities (Fig. 2B). In addition to NF-
κB and AP-1 motifs to modulate the enhancer's activity,
other positive regulatory elements have been identified
within the iEκ, including κA and E-box motifs, these
sequences could potentially regulate the activity of iEκ
[33,34]. Therefore, other transcription factors bind to
kappa gene through various signaling pathways to regu-
late kappa expression in NPC cells can not be excluded at
this time.
In B cells, functional analyses of motifs within iEκ per-
formed using isolated enhancers to activate reporter genes
in transfection assays have shown that B cell-specific activ-
ity of iEκ depends substantially on the κB element [39].
Moreover, mutations of E-box motifs have variable and
weaker effects on transcription compared to mutation of
the κB site [16]. These observations indicated NF-κB acts
as the master and commander of kappa gene expression
via the κB motif in iEκ in B cells. Similarly, our result indi-
cated mutation of the NF-κB motif displayed a more
inhibitory effect on LMP1-increased iEκ activity compared
to mutation of the AP-1 site, suggested that of NF-κB and
AP-1 pathways, NF-κB pathway may play a leading role in
LMP1-augmented iEκ activity in NPC cells.
Transcripition factor NF-κB comprised of homo- and het-
erodimers of the p65 (RelA), RelB, c-Rel, p50/p105 (NF-
κB1) and p52/p100 (NF-κB2) polypeptides can both
induce and repress gene expression by binding to discrete
κB elements in promoters and enhancers [40]. NF-κB is
found in the cytoplasm of pre-B cell lines as an inactive
complexes associated with an IκB inhibitor, whereas in
mature and transformed B cells, NF-κB is active and local-
ized in the nucleus. NF-κB DNA binding activity and
nuclear relocalization can be activated by a variety of stim-
uli. In our previous study, IκBα phosphorylation accom-
panying by IκBα degradation has been found in NPC cells
and LMP1 can further induced IκBα phosphorylation and
degradation [1]. Our results presented here indicated
LMP1 increased the released-NF-κB translocating freely to
the nucleus (Fig. 4E) and binding to the κB motif of iEκ
(Fig. 4A, lane 3). We characterized the NF-κB/DNA com-
plex containing p52 and p65 subunits by Gel Super-shift
assay (Fig. 4C, lanes 5 and 6). We also found LMP1
induced the processing of p100 to p52 (Fig. 4F) and the
nuclear translocation of p52 (Fig. 4G). Generally, p50/
p65 is considered as a 'classical' heterodimers. p52 forms
heterodimers with other NF-κB subunits, such as p65 and
RelB, or as a homodimer has also been found [41]. How-
ever, in our experiments, we failed to detect p50, c-Rel and
RelB subunits in NF-κB/DNA complex. We also con-
firmed the interaction of p52 and p65 at endogenous lev-
els by co-IP assay (Fig. 5). Moreover, both p52 and p65
could directly bind to the NF-κB binding region within
the iEκ enhancer (Fig. 8B). Perkins [42] found that p52/
p65 preferentially activates HIV-1 gene expression relative
to the p50/p65 heterodimers, which is similar to our
results. The results suggest that a heterodimer of p65 with
p52 subunit binding to κB site within the iEκ may play an
important role in upregulating the activity of iEκ and
kappa light chain production in HNE2-LMP1 NPC cells.
We reported earlier that NPC cells express activated forms
of JNK (pJNK) whether LMP1-negative or LMP1-positive
and LMP1 can increase the phosphorylation level of JNK
[1]. JNK is one of the kinases that regulated the activation
of AP-1 transcription factor. Upon stimulation, this pro-
tein kinase enters the nucleus to induce or phosphorylate
subunits of AP-1 and the resultant enhanced AP-1 activity
can then participate in the regulation of gene expression.
The AP-1 transcription factor is a dimeric complex that
comprises a group of structurally and functionally related
members of the Jun family (c-Jun, JunB and JunD), Fos
family (c-Fos, FosB, Fra-1 and Fra-2), ATF (ATFa, ATF-2
and ATF-3) and JDP (JDP-1 and JDP-2) subfamilies,
which can bind to AP-1 consensus sequence 5'-TGAG/
CTCA-3' [43]. Different types of AP-1 complexes are func-
tionally distinct and may activate different target genes
[44]. By EMSA analysis, we showed that nuclear extracts of
both HNE2 and HNE2-LMP1 cells could bind κAP-1
motif and LMP1 was able to increase this binding (Fig. 6A,
lanes 2 and 3). Super-EMSA further characterized the pro-
tein/DNA complex containing c-Jun and c-Fos transcrip-
Co-IP of endogenous c-Jun and c-Fos Figure 7
Co-IP of endogenous c-Jun and c-Fos. Non-denatured 
nuclear extracts prepared from HNE2-LMP1 cells were 
immunoprecipitated with anti-c-Jun, anti-c-Fos or control 
IgG antibody. The immune complexes and the input (10% of 
the nuclear extracts used in the immunoprecipitation step) 
were analyzed by immunoblotting with antibody specific to c-
Fos (upper panel, lanes 1-3) or c-Jun (lower panel, lanes 4-6). 
The same membrane was stripped and reprobed to detect c-
Jun (lower panel, lanes 1-3) or c-Fos (upper panel, lanes 4-6). 
Asterisks marked the specific bands recognized by c-Fos anti-
body.Molecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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p52/p65 and c-Jun/c-Fos heterodimers interacted with the human Ig kappa intronic enhancer and the adjacent sequence in vivo Figure 8
p52/p65 and c-Jun/c-Fos heterodimers interacted with the human Ig kappa intronic enhancer and the adjacent 
sequence in vivo. (A) DNA sonication. 2% ethidium bromide-stained agarose gel demonstrated the shearing of chromatin 
from HNE2-LMP1 cells. Average chromatin length was ~500 bp. (B) ChIP analysis of the NF-κB binding site within the iEκ 
enhancer in HNE2-LMP1 cells. The cross-linked chromatin was precipitated with specific antibodies as indicated. The positive 
control was represented by the input fraction. Negative controls included a no chromatin sample, no antibody sample, and 
nonspecific antibody (αIgG). Precipitated DNA was analyzed by PCR using primers that amplified a 159-bp region that included 
the NF-κB site. (C) ChIP analysis of the AP-1 site located downstream of the iEκ enhancer. The PCR primers amplified a 188-
bp sequence that included the AP-1 site.
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tion factors (Fig. 6C). Moreover, our results demonstrated
LMP1-induced JNK phosphorylation level coincided with
the phosphorylation level of c-Jun at Ser63 and Ser73 in
the nucleus (Fig. 6D) and this c-Jun phosphorylation was
much closely related to the DNA binding activity of the c-
Jun/c-Fos heterodimer. Similar results that the phosphor-
ylation level of c-Jun (ser63, ser73) is related to the DNA
binding activity of c-Jun/JunB heterodimer was reported
[23]. Our results suggest that LMP1 can act through acti-
vation of JNK, a c-Jun N-terminal kinase needed for AP-1
activation and induce formation of the c-Jun/c-Fos/DNA
complex to upregulate the activity of iEκ in NPC cells. We
also found stable expression of TAM67 almost completely
blocked LMP1-induced AP-1 DNA binding in HNE2-
LMP1 cells (Fig. 6A, lane 4). Similar results that stable
TAM67 expression completely inhibited MKK6-induced
AP-1 binding in MCF-7 cells [45] and an inhibition of
nickel-induced AP-1 element binding by TAM67 in
human bronchial epithelial cells [46] were recently
reported. Although we have demonstrated the het-
erodimerization of c-Jun and c-Fos (Fig. 7) and this het-
erodimer can directly bind to the AP-1 site located near
the iEκ enhancer (Fig. 8C), we have used only c-Jun and c-
Fos in this report, therefore, other dimeric forms of AP-1
transcription factor involved in regulating the iEκ activity
in NPC cells can not be excluded at this time.
Conclusion
The present study presented novel experimental proofs on
the mechanisms upregulating the expression of kappa
light chain by LMP1 in NPC cells. Since other virus-
encoded oncoproteins, such as HBX, E6, E7, can also acti-
vate many signal pathways including NF-κB and AP-1
pathways. These oncoproteins might induce immu-
noglobulin gene expression through the mechanism sim-
ilar to EBV-LMP1. Our study might offer a new insight
into the molecular mechanisms by which nonlymphoid
cancer cells expressing immunoglobulin and lay founda-
tions for further studies.
Methods
Cell lines and cell culture
HNE2, HNE2-LMP1, HNE2-LMP1-DNMIκBα and HNE2-
LMP1-TAM67 cell lines used were as previously described
[1]. All the cell lines were maintained in RPMI1640
(GIBCO) supplemented with 10% FBS (GIBCO), 1%
glutamine, and 1% antibiotics at 37°C in humidified
atmosphere with 5% CO2.
Chemicals and cell treatments
The selective JNK inhibitor SP600125 (Cat No.420119,
Calbiochem) and NF-κB inhibitor Bay11-7082 (Cat
No.196870, Calbiochem) were prepared as a stock solu-
tion of 20 mM in dimethylsulfoxide (DMSO, Sigma).
Subconfluent cells were treated with the compound at
indicated concentrations for indicated time. Detailed
treatment procedures were described in figure legends.
The final concentration of DMSO in the culture media
was kept less than 0.1% which had no significant effect on
the cell growth.
Plasmid constructs
The human Iα promoter was a 342 bp promoter fragment
identical to that used previously [32], obtained by ampli-
fication from human HNE2 cells genomic DNA. The sense
primer 5'-gagctcctctgtctcggggtctctga-3' used in this reaction
was carrying SacI cloning site whereas the antisense
primer 5'-aagcttccgtctgtccttagcagagc-3' had Hind  III site.
Italic nucleotides represent restriction endonuclease rec-
ognition sites. This fragment was inserted into the Sac I/
Hind III sites of the pGL3-Basic vector (Promega) and the
plasmid was designated as pGL3-α.
A 575 bp fragment containing the intact human iEκ and
the AP-l binding site at the 3' flank of iEκ was cloned.
Briefly, a 575 bp DNA fragments containing human
kappa light chain genomic sequences were amplified from
HNE2 cells genomic DNA by PCR using specific primers
from the human Ig kappa gene (GenBank accession no.
NG_000834): 5'-ggatccctgacttctccctatctgtt-3'(sense),
which contains an artificial BamH I site, and 5'-gtcgacccat-
tctgagggctttgc-3'(antisense), which contains an artificial
Sal I site. Italic nucleotides represent restriction endonu-
clease recognition sites. The PCR-amplified fragments
were then digested with BamH I/Sal I and inserted into the
corresponding restriction sites of the pGL3-α plasmid
described above to generate pα-iEκwt. The PCR products
were confirmed by their size, as determined by electro-
phoresis and by DNA sequencing. The NF-κB motif and
the AP-1 motif mutants (designated as pα-iEκ-mtκB and
pα-iEκ-mtAP-1, respectively) from pα-iEκwt were gener-
ated by PCR based on an overlap extension technique
[47]. The primers used for generating mutations were: 5'-
ccccagagagagattgccaagaggccacctg-3' and 5'-
ttggcaatctctctctgggggattc-3' (for NF-κB site), 5'-gaggctttcct-
ggactcagccgctgcc-3' and 5'-gctgagtccaggaaagcctccg-3' (for
AP-1 site). PCR-amplified fragments carrying the desired
mutations were then cloned into BamH I/Sal I sites of the
pGL3-α plasmid. Bold nucleotides represent sequences of
κNF-κB (ggggatttcc) and κAP-1(tgactca) motifs and bold
italic nucleotides represent mutated nucleotides. The
expected mutations and the integrity of the enhancer were
confirmed by automated sequencing using an Applied
Biosystems sequencer and software (Foster City, CA).
The pSG5-based expression vector for wild-type LMP1
derived from B95.8 EBV strain was kindly provided by Dr.
Izumi (Brigham and Women's Hospital). Expression plas-
mid of dominant negative mutant of IκBα (DNMIκBα),
which had a deletion of 71 amino acids at the N terminusMolecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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and was cloned into the multiple cloning sites of
pcDNA3, was kindly provided by Dr. Krappmann (Max-
Delbruck-center for Molecular Medicine, Berlin, Ger-
many). Expression plasmid of mutant c-Jun (TAM67) was
constructed by inserting the TAM67 sequence into the vec-
tor pGem3z which contains a human keratin 14 promoter
and a human growth hormone segment, was kindly pro-
vided by Dr. J. Li (NCI, Frederich, U.S.A.).
Luciferase reporter assays
The pGL3-α, pα-iEκwt, pα-iEκ-mtκB and pα-iEκ-mtAP-1
luciferase reporter plasmids described above were used in
conjunction with the control pGL3-Basic vector
(Promega) and the internal control plasmid pRL-SV40
(Promega). Cells were cultured in 24-well plates at a den-
sity of 1 × 105 per well overnight and were transfected with
Lipofectamine™ 2000 (Invitrogen) as per the manufac-
turer's instructions. Each transfection contained 800 ng/
well of firefly luciferase reporter and 80 ng/well of internal
control pRL-SV40 or contained 400 ng/well of firefly luci-
ferase reporter and 80 ng/well of internal control pRL-
SV40 together with 200 ng/well of each expression plas-
mid or blank expression plasmid necessary to normalize
the amount of DNA transfected. 24 hrs after transfection,
cells were either left untreated or treated with 20 μM
Bay11-7082, 20 μM SP600125 or 0.1% DMSO for 12 hrs.
Cells were harvested at 36 h after transfection and lysates
were analyzed for luciferase activity using the Dual Luci-
ferase Reporter assay (Promega) according to the manu-
facturer's directions with a GloMax™ Microplate
Luminometer (Promega). The luciferase reporter plas-
mids were co-transfected with pRL-SV40 to correct for var-
iations in transfection efficiency. The relative luciferase
activity normalized to the value of pRL-SV40 activity.
Results were expressed as fold induction of pGL3-Basic
activity, which was assigned a value of 1. The data repre-
sent the mean ± SD of the three independent experiments
performed in triplicate.
Western blot analysis
Whole cell lysates preparation and western blot analysis
were performed according to the method previously
described [1]. Nuclear or cytoplasmic extracts were pre-
pared by the use of NE-PER Nuclear and Cytoplasmic
Extraction Kit (Cat. No.78833, Pierce) in accordance with
the manufacturer's protocol. Protein concentration was
determined by BCA Assay Reagent (Cat. No.23228,
Pierce). The following antibodies were used for immuno-
detection with appropriate dilutions: mouse LMP1 mon-
oclonal antibody (CS.1-4, DAKO); p52(sc-298), p65(sc-
8008), c-Jun(sc-44), c-Fos(sc-52), nucleolin(sc-8031), α-
tubulin(sc-5286), goat anti-rabbit IgG-HRP (sc-2004),
goat anti-mouse IgG-HRP (sc-2005) and donkey anti-goat
IgG-HRP (sc-2020) (all from Santa Cruz); phospho-
JNK(Thr183/Tyr185)(9251), phospho-c-Jun(Ser63)
(9261S) and phospho-c-Jun (Ser73) (9164S) (all from
Cell Signaling Technology).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared by the use of NE-PER
Nuclear and Cytoplasmic Extraction Kit (Cat. No.78833,
Pierce) in accordance with the manufacturer's protocol.
The protein concentration in nuclear extracts was deter-
mined using the BCA protein assay reagent (Cat.
No.23228, Pierce) and EMSAs were carried out using aliq-
uots containing equal amounts of protein. EMSA analysis
was performed using the LightShift™ Chemiluminescent
EMSA Kit (Cat. No.20148, Pierce) following the manufac-
turer's instructions. The reaction mixtures (20 μl) contain-
ing about 10 μg nuclear extracts were incubated with 2
nmol/L of the biotin-labeled double-stranded oligonucle-
otide probes in reaction buffer (Pierce) for 20 min at
room temperature. Samples were subjected to electro-
phoresis in 5% nondenaturing polyacrylamide gel and
transferred to Biodyne™ B Nylon membrane (Cat.
No.77016, Pierce). For competition analyses, 200-fold
excess of the unlabeled wild-type or mutant or nonspecific
probe was included in the binding reaction. For antibody
supershift experiments, the reaction mixtures were prein-
cubated with 2 μg of p50(sc-8414X), p52(sc-298X),
p65(sc-8008X), c-Rel(sc-272X), RelB(sc-226X), c-Jun(sc-
44X), c-Fos(sc-52X) and rabbit IgG(sc-2027) antibody
(all from Santa Cruz) at room temperature for 1 hr. The
complementary oligonucleotides used as probes or com-
petitors were listed below: the human κNF-κB oligonucle-
otides used were 5'-ccagagggggatttccaagaggcca-3' and 5'-
tggcctcttggaaatccccctctgg-3', derived from the sequence of
the NF-κB site within the human kappa intron enhancer.
The human κAP-l oligonucleotides used were 5'-gctttcctt-
gactcagccgctgcc-3' and 5'-ggcagcggctgagtcaaggaaagc-3',
derived from the AP-1 sequence ~320 bp 3' of the κNF-κB
site. The nonspecific oligonucleotides used as competitor
DNA for κNF-κB and κAP-l were κAP-l and κNF-κB oligo-
nucleotides, respectively. The mutated κNF-κB oligonu-
cleotides used were 5'-ccagagagagattgccaagaggcca-3' and
5'-tggcctcttggcaatctctctctgg-3' (designated as mutκB). The
mutated  κAP-l oligonucleotides used were 5'-gctttcct-
ggactcagccgctgcc-3' and 5'-ggcagcggctgagtccaggaaagc-3'
(designated as mutAP-l). Binding sites were shown in
bold type and mutated nucleotides were shown in bold
italic. The mutated oligo probes for NF-κB and AP-1 bind-
ing sites in EMSAs were identical to those of the mutated
sequences in the reporter gene constructs.
Co-immunoprecipitation (Co-IP)
Non-denatured nuclear proteins were purified using NE-
PER Nuclear and Cytoplasmic Extraction Kit (Cat.
No.78833, Pierce) according to the manufacturer's
instructions. Protein concentration was determined by
BCA Assay Reagent (Cat. No.23228, Pierce). 200 μg ofMolecular Cancer 2009, 8:92 http://www.molecular-cancer.com/content/8/1/92
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nuclear extracts prepared from HNE2-LMP1 cells were
mixed with 40 μl protein A-Sepharose beads (Sigma) in
the immunoprecipitation assay buffer (1× PBS, 0.5%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS),
incubated at 4°C for 2 h with gentle agitation and centri-
fuged for 2 min at 2000 rpm for preclearing. The recov-
ered supernatant was incubated with 2 μg of an antibody
to a member of the complex in the presence of 1× protease
inhibitors at 4°C overnight with mild shaking. Then, 50
μl of protein A-Sepharose beads was added, and the incu-
bation was continued for 2 h at 4°C with gentle shaking.
Protein A-precipitated protein complex was recovered by
brief centrifugation, followed by three times washes with
immunoprecipitation assay buffer. The harvested beads
resuspended in 30 μl of 2× SDS PAGE sample buffer were
boiled for 5 min to release the bound protein. The sam-
ples were then analyzed by Western blot with a specific
antibody to another member of the complex. A 20 μg aliq-
uot of nuclear extract was used as an input control. The
same membrane was stripped by incubating at 50°C for
half an hour in stripping buffer [100 mM β-mercaptoeth-
anol, 2% (wt/vol) sodium dodecyl sulfate and 62.5 mM
Tris-HCl (pH 6.8)] and reprobed with the corresponding
IP antibody.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using the ChIP assay kit (Upstate
Biotechnology, Lake Placid, NY) and was then conducted
according to the manufacturer's recommendations.
Briefly, formaldehyde solution was added directly to
HNE2-LMP1 cells at a final concentration of 1% at room
temperature for 10 min. Then the cells was neutralized
with glycine at room temperature for 5 min and washed
twice with ice-cold 1× phosphate-buffered saline contain-
ing protease inhibitors. The cells were lysed by SDS lysis
buffer with protease inhibitors. Chromatin in the lysate
(350 μl) was sheared by sonication with a Branson Soni-
fier Cell disruptor B15 (output control 4, duty cycle 40%),
with 14 cycles of 20-second pulses and 20-second inter-
vals to an average length of ~500 bp as determined by 2%
agarose gel electrophoresis. The suspension was pre-
cleared with salmon sperm DNA/protein A/agarose-50%
slurry for 1 h at 4°C. After "precleared" the chromatin, a
small aliquot (10 μl) was saved as "input DNA" for PCR
analysis later. Other each 100 μl aliquots of sheared cross-
linked chromatin were incubated with 2 μg each of anti-
bodies p50(sc-8414X), p52(sc-298X), p65(sc-8008X), c-
Rel(sc-272X), RelB(sc-226X), c-Jun(sc-44X), c-Fos(sc-
52X), rabbit IgG(sc-2027) (Santa Cruz), or no Ab over-
night at 4°C with mild shaking. The immune complexes
were incubated with salmon sperm DNA/protein A/agar-
ose-50% slurry with mild shaking for 2 h at 4°C, washed,
and eluted. Cross-links were reversed by 5 M NaCl. After
proteinase K digestion, DNA in samples was phenol
extracted, ethanol precipitated, and resuspended in 50 μl
of ddH2O. Two microliters of DNA solution was used for
36 cycles of PCR amplification. PCR products were ana-
lyzed by electrophoresis on a 2% agarose gel and visual-
ized by ethidium bromide staining. The following primers
were used in the ChIP assays: human iEκ enhancer includ-
ing the NF-κB-binding region, 5'-ctactgctctcccacccaac-3'
and 5'-tgcagcaattttcagccata-3'(159 bp); the AP-1-binding
region located downstream the human iEκ enhancer, 5'-
gcctgttatcccagcacagt-3' and 5'-tgcatgcttttctgaccttg-3'(188
bp).
Statistical analysis
All statistical calculations were performed with the statis-
tical software program SPSS ver.12.0. Differences between
various groups were evaluated by the Student's t test. The
difference was of statistical significance, when P < 0.05.
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